Close

Jefferies Downgrades TCR2 Therapeutics (TCRR) to Hold

March 9, 2023 2:30 AM EST Send to a Friend
Jefferies analyst Kelly Shi downgraded TCR2 Therapeutics (NASDAQ: TCRR) from Buy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login